The main goal of this study was to accelerate the translation of the beneficial effects of HDAC6 inhibition seen in a CMT2 mouse model [13] into a pharmacological therapy for patients with CMT for which currently no treatment exists. The gene discussed is HDAC6; the disease is Charcot-Marie-Tooth disease type 2.